Trials / Completed
CompletedNCT05640960
Undifferentiated Embryonal Sarcoma of the Liver: Evaluation of the Relapse Profile According to the Therapies Administered
Undifferentiated Embryonal Sarcoma of the Liver
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- University Hospital, Strasbourg, France · Academic / Other
- Sex
- All
- Age
- 1 Year – 25 Years
- Healthy volunteers
- —
Summary
Undifferentiated embryonal sarcoma of the liver is the 3rd most common malignant liver tumor after hepatoblastoma and hepatocellular carcinoma with a peak incidence between 6 and 10 years of age. Historically, it is a tumor treated only by surgery with a poor prognosis. In the last decade, the combination of more intensive chemotherapy and, more randomly, radiotherapy, has significantly improved the survival rate of these patients. Due to its low incidence, there are few series reported in the literature and to date there is no specific treatment protocol for the management of these tumors. It seems appropriate to review the management of these tumors in France in order to discuss the best therapeutic strategy.
Conditions
Timeline
- Start date
- 2020-09-11
- Primary completion
- 2021-11-11
- Completion
- 2021-12-31
- First posted
- 2022-12-07
- Last updated
- 2023-12-08
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05640960. Inclusion in this directory is not an endorsement.